Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 17/20 | 0.57 |
| ▸ | TSPO | P30536 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429948 | 0.85 | STIM1 (0.58) | P2RY14TSPOTMEM97S1PR1OPRD1 | |
| SCHEMBL1429953 | 0.84 | STIM1 (0.62) | P2RY14TSPOTMEM97S1PR1STIM1 | |
| SCHEMBL1430355 | 0.80 | STIM1 (0.48) | P2RY14TSPOTMEM97S1PR1OPRD1 | |
| SCHEMBL1429851 | 0.80 | S1PR1 (0.55) | P2RY14TSPOTMEM97S1PR1STIM1 | |
| SCHEMBL20534223 | 0.79 | P2RY14 (0.87) | P2RY14OPRD1 | |
| SCHEMBL12420391 | 0.78 | STS (0.59) | S1PR1STSSTIM1ORAI1 | |
| SCHEMBL12420394 | 0.78 | PTGS2 (0.63) | S1PR1 | |
| SCHEMBL12420393 | 0.75 | S1PR1 (0.58) | S1PR1STIM1ORAI1 | |
| SCHEMBL2711661 | 0.75 | STIM1 (0.67) | P2RY14STSSTIM1ORAI1 | |
| SCHEMBL29531298 | 0.75 | BRD4 (0.50) | P2RY14OPRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | claimed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | claimed |
| CN-102076670-A | Compounds and methods for modulating g protein-coupled receptors | IRM LLC | 2011-05-25 | — | — | CN | claimed |
| EP-2300442-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | claimed |
| CN-102076670-B | Compounds and methods for modulating g protein-coupled receptors | IRM LLC | 2013-05-22 | — | — | CN | disclosed |
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| CN-102076670-A | Compounds and methods for modulating g protein-coupled receptors | IRM LLC | 2011-05-25 | — | — | CN | disclosed |
| EP-2300442-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | P2RY14 391/4885TSPO 581/4885TMEM97 548/4885 |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | P2RY14 391/4885TSPO 581/4885TMEM97 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.